Hyperfibrotic myelodysplasia - a possible new entity (review)

Area of Science:

• Hematology
• Oncology
• Bone Marrow Pathology

Background:

• Myelofibrosis is observed in myeloproliferative diseases (MPD) and acute myeloid leukemias (AML).
• Myelofibrosis is rare in primary myelodysplastic syndromes (MDS).
• H-MDS exhibits distinct characteristics suggesting it may be a separate entity.

Purpose of the Study:

• To review contrasting opinions on H-MDS.
• To summarize features distinguishing H-MDS from classical MDS.
• To explore the potential classification of H-MDS.

Main Methods:

• Literature review of H-MDS case series.
• Analysis of clinical and cytogenetic features.
• Discussion of pathogenetic mechanisms.

Main Results:

• H-MDS is considered a transitional stage between MDS and MPD, an MPD transformation, or de novo AML.
• Pathogenesis may involve abnormal megakaryocytes, similar to MPD.
• Karyotype abnormalities are significant.
• Clinical features are heterogeneous, with survival similar to classical MDS.

Conclusions:

• H-MDS presents unique features differentiating it from classical MDS.
• Diagnosis necessitates trephine biopsy and cytogenetic analysis.
• Larger patient series are required for definitive classification of H-MDS.